Belite Bio, Inc (BLTE)
Belite Bio is a San Diego drug developer working on oral treatments for degenerative retinal diseases that cause vision loss. It last closed at $127.38 on Nov 20, down 15.65% on the day. Over the last 12 months BLTE insiders bought $0 of stock on the open market and sold $41.0M, according to SEC Form 4 filings.
Key Stats
Fiscal 2025Not reported for this period.
From BLTE's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.
- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on BLTE
Technical AnalysisPrices may be delayed
The stock is 20% below its 20 day and 24% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the Pivot S1 at $119.90, and the nearest resistance the Pivot at $127.48.
| RSI (14) | 31.58 | Weak, oversold below 30 | Neutral |
| MACD | -1.80 | Below its signal line | Bearish |
| Stochastic | 33.0 | Middle of its range | Neutral |
| ADX (14) | 19.0 | No clear trend | |
| Williams %R | -85.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -288.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.4% | Change over 10 sessions | Bearish |
| ATR (14) | $9.34 | Typical daily range, 7.3% of price |
| RSI (14) | 39.11 | Weak, oversold below 30 | Neutral |
| MACD | -1.20 | Below its signal line | Bearish |
| Stochastic | 24.3 | Middle of its range | Neutral |
| ADX (14) | 25.3 | Trending down | |
| Williams %R | -90.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -159.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −26.7% | Change over 10 sessions | Bearish |
| ATR (14) | $18.43 | Typical daily range, 14.5% of price |
What happened before
See how BLTE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BLTE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options FlowPrices may be delayed
90DNo whale options trades in BLTE in the last 90 days.
Dark PoolPrices may be delayed
30DBLTE Institutional Ownership
Full report →- ▲57 buying vs 42 selling
- ●Held by funds -0.1 pts
- ▲Funds holding +15
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 96 | 81 | +18.5% |
| In funds' top 10 | 5 | 5 | 0.0% |
| Held by funds | 23.9% | 24.1% | −0.1 pts |
| New / increased | 28 / 29 | 22 / 28 | +14.0% |
| Reduced / sold out | 30 / 12 | 22 / 17 | +7.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
BLTE Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 12 | Hendrik Peter SchollChief Medical Officer | Sale plan | 2,000 | $165.99 | $332K |
| Oct 1 | Hendrik Peter SchollChief Medical Officer | Sale plan | 500 | $165.32 | $83K |
| Sep 8 | Hao-Yuan ChuangCFO | Sale plan | 67,395 | $189.98 | $12.8M |
| Sep 8 | Yu-Hsin LinCEO | Sale plan | 100,435 | $190.00 | $19.1M |
| Aug 12 | Yu-Hsin LinCEO | Sale plan | 365 | $180.35 | $66K |
| Aug 12 | Hao-Yuan ChuangCFO | Sale plan | 367 | $180.35 | $66K |
From SEC Form 4 filings by BLTE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLTE is in one of them and how their past BLTE trades turned out.
BLTE News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BLTE in an article yet. Here's the latest on the wider market.
About Belite Bio
Belite Bio is a drug development company based in San Diego, California. It is developing tinlarebant, a tablet taken once a day, for people with degenerative retinal diseases that cause progressive vision loss, including geographic atrophy and Stargardt disease type 1. The company also has an earlier stage oral compound aimed at metabolic conditions such as fatty liver disease and type 2 diabetes. Its intended users are patients with these eye conditions and the doctors who would treat them if a product is approved.
- Headquarters
- San Diego, CA



